查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1268950

全球疫苗佐劑市場 - 2023-2030

Global Vaccine Adjuvants Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球疫苗佐劑市場預計將出現利潤豐厚的增長，到 2022 年將達到 7.397 億美元，到 2030 年將達到 18.192 億美元。 全球疫苗佐劑市場預計在預測期內（2023-2030 年）的複合年增長率為 12.2%。 涉及疫苗佐劑的市場參與者正在推進新產品的開發，預計這將在未來幾年推動疫苗佐劑市場的增長。

例如，2021 年 10 月，生物製藥公司 Dynavax Technologies Corporation 專注於疫苗的開發和商業化。 美國國防部 (DOD) 宣布 Dynavac 已獲得一份價值約 2200 萬美元的合同，為期兩年半，用於開發重組 CpG 1018 佐劑鼠疫疫苗。 根據該協議，Dynavacs 將進行 2 期臨床試驗，將 CpG 1018 佐劑與 DOD 的 rF1V 疫苗相結合。 公司將於2022年開始二期臨床試驗。

全球疫苗佐劑市場受到傳染病流行、對更有效疫苗的需求以及因 COVID-19 大流行而不斷增長的疫苗需求的推動。 由於在開發新的有效疫苗時對疫苗佐劑的需求不斷增加，預計全球疫苗佐劑市場將出現顯著增長。

市場動態

傳染病流行帶動全球疫苗佐劑市場增長

在預測期內，由於全球傳染病流行的加劇，預計全球疫苗佐劑市場的增長將會加快。 例如，疫苗接種是預防傳染病最有效的策略之一。 結核病是繼 COVID-19 之後世界上最致命的傳染病之一，耐藥結核分枝桿菌仍然是一個主要問題。

例如，美國疾病控制和預防中心報告稱，2022 年美國將有 8,300 例確診的結核病病例。 堅持結核病的人數約為每 100,000 人 2.5 例。 因此，這些原因將增加疫苗中佐劑的使用，推動全球疫苗佐劑市場的增長。

輔助開發的高研發成本阻礙了市場增長

製造商面臨的主要挑戰之一是與開發新疫苗佐劑相關的高研發成本。 研發和臨床試驗成本高昂，需要獲得投資回報，這可能會成為十年或更長時間的資本限制。

單一疫苗的研發成本基線估計（通常指新藥開發成本）在 10 億美元到 20 億美元之間。 這些高成本的原因是高失敗率（經常被引用的是，FDA 批准了 5,000 到 10,000 種篩選化合物中的 1 種）。

COVID-19 影響分析

COVID-19 大流行對疫苗產生了前所未有的需求，而佐劑在增強這些疫苗的功效方面發揮著重要作用。 例如，Pfizer-BioNTech 疫苗和 Moderna COVID-19 疫苗都使用佐劑來增強人體對疫苗的免疫反應。 這在短期內推動了全球疫苗佐劑市場的增長。

然而，由於世界各地的旅行限制和封鎖，疫苗佐劑的運輸和分配一直很困難。 結果導致特異性佐劑短缺，延誤了一些疫苗的研發和生產。 例如，Bharat Biotech 的 Covaxin 因佐劑短缺而面臨供應鏈中斷，減緩了在一些國家的分銷。

俄烏衝突分析

全球疫苗佐劑市場可能會受到俄羅斯和烏克蘭之間持續衝突的影響。 這是因為俄羅斯是氫氧化鋁的主要供應商，氫氧化鋁是疫苗中常用的一種佐劑。 由於衝突而中斷這些佐劑的供應鏈可能導致佐劑依賴性疫苗的短缺。

內容

第 1 章研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按產品類型分類的摘要
  • 按給藥途徑分類的片段
  • 疾病片段
  • 最終用戶的片段
  • 區域摘要

第四章市場動態

  • 影響因素
    • 司機
      • 在預測期內，傳染病的流行推動了全球疫苗佐劑市場的增長
    • 約束因素
      • 輔助開發的高研發成本阻礙了市場增長
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第 7 章按產品類型

  • 顆粒佐劑
  • 佐劑乳液
  • 病原體成分
  • 伴隨佐劑
  • 其他

第8章給藥途徑

  • 肌肉注射
  • 口語
  • 皮內
  • 皮下
  • 鼻內

第9章疾病

  • 感染
  • 癌症
  • 其他

第 10 章最終用戶

  • 製藥和生物技術公司
  • 關於研究機構
  • 其他

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 競爭場景
  • 市場分析/份額分析
  • 併購分析

第13章公司簡介

  • InvivoGen
    • 公司簡介
    • 產品組合和說明
    • 財務摘要
    • 主要發展
  • OZ Biosciences
  • SEPPIC
  • SPI Pharma
  • Agenus, Inc
  • Aphios Corp
  • Vaxine Pty Ltd
  • Seqirus
  • Chemtrade
  • Croda International

第14章 附錄

簡介目錄
Product Code: PH1707

Market Overview

The global vaccine adjuvants market reached US$ 739.7 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 1,819.2 million by 2030. The global vaccine adjuvants market is expected to exhibit a CAGR of 12.2% during the forecast period (2023-2030). Market players involved in vaccine adjuvants are developing new products, which is expected to promote vaccine adjuvants market growth in the coming years.

For instance, in October 2021, Dynavax Technologies Corporation, a biopharmaceutical company, focused on developing and commercializing vaccines. The U.S. Department of Defense (DOD) announced that Dynavax had executed an agreement for approximately $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018. Under the agreement, Dynavax will conduct a Phase 2 clinical trial combining its CpG 1018 adjuvant with the DOD's rF1V vaccine. The company commenced the Phase 2 trial in 2022.

The global vaccine adjuvants market is being driven by the growing prevalence of infectious diseases, the need for more effective vaccines, and the rising demand for vaccines due to the COVID-19 pandemic. The global vaccine adjuvants market is expected to have significant growth due to increasing demand for vaccine adjuvants in the development of new and effective vaccines.

Market Dynamics

The increasing prevalence of infectious diseases to drive global vaccine adjuvants market growth

An increase in the prevalence of infectious diseases across the globe is expected to augment the growth of the global vaccine adjuvants market during the forecast period. For instance, vaccination is one of the most efficient strategies for the prevention of infectious diseases. Tuberculosis (TB) is one of the world's deadliest infectious diseases, second only to COVID-19, and drug-resistant TB strains are still a major concern.

For instance, according to the Centers for Disease Control and Prevention report, 8,300 TB cases were observed in the U.S. in 2022. Also, the incidene of TB adherence was about 2.5 cases per 100,000 persons. Therefore, owing to these reasons, the usage of adjuvants in vaccines will increase, thereby boosting the global vaccine adjuvants market growth.

High R&D cost for adjuvant development to hamper the market growth

One of the major challenges faced by the manufacturers is the high research & development cost associated with developing a new vaccine adjuvant. Costs associated with research, development, and clinical studies are high, and the company has to recoup its investment which could have tied up capital for a decade or more.

The estimated R&D cost for a single vaccine is often based on development costs for new drugs and is in the range US$ 1-2 billion. A reason for these high costs is high failure rates (it is often cited that only 1 in every 5,000-10,000 compounds screened is approved by the FDA).

COVID-19 Impact Analysis

The COVID-19 pandemic has led to an unprecedented demand for vaccines, and adjuvants have played a critical role in enhancing the efficacy of these vaccines. For example, the Pfizer-BioNTech and Moderna COVID-19 vaccines both use adjuvants to boost the body's immune response to the vaccine. This has driven the growth of the global vaccine adjuvants market in the short term.

However, with global travel restrictions and lockdowns in place, it was difficult to transport and distribute vaccine adjuvants. This has led to shortages of certain adjuvants, which has slowed down the development and production of some vaccines. For example, Bharat Biotech Covaxin faced supply chain disruptions due to the shortage of the adjuvant, which slowed down its distribution in some countries.

Russia Ukraine Conflict Analysis

The global market for vaccine adjuvants may be affected by the ongoing conflict between Russia and Ukraine, as Russia is a major provider of aluminum hydroxide, a commonly used adjuvant in vaccines. Disruptions in the supply chains of these adjuvants due to the conflict could lead to a shortage of vaccines that depend on them.

Segment Analysis

The global vaccine adjuvants market is segmented based on product type, route of administration, disease, end user, and region.

Particulate adjuvants segment to hold the highest market share in the global vaccine adjuvants market

The particulate adjuvants segment is expected to dominate and account fo a 30.2% global vaccine adjuvant market share over the forecast period. Delivery systems (particulate adjuvants) cover materials such as lipid particles, aluminum salts (alum), and microparticles. Alum is by far the most commonly used adjuvant. This adjuvant is in the formulation of licensed vaccines against diphtheria/tetanus/pertussis (DTP), Hepatitis A (HAV), and Hepatitis B (HBV).

Thereby, the increasing prevalence of infectious diseases, the growing demand for vaccines, and the need for more effective vaccines will result in the growth of this segment over the forecast period.

Geographical Analysis

The presence of major players to dominate the North America region.

North America is expected to have a dominant global vaccine adjuvants market share of around 1/3rd of this market, as the U.S. is the largest revenue contributor in North America due to the increasing elderly population, rising prevalence of cancers, high R&D for cancer diagnostics, and development of innovative products by manufacturers in the region.

Also, the presence of major players such as, in the U.S., GlaxoSmithKline (GSK) is a leading player in the vaccine adjuvants market. The company's AS03 adjuvant has been used in several vaccines, including the H1N1 flu vaccine and the Shingrix vaccine for shingles.

Competitive Landscape

The major global players in the market include: InvivoGen, OZ Biosciences, SEPPIC, SPI Pharma, Agenus, Inc, Aphios Corp, Vaxine Pty Ltd, Seqirus, Chemtrade, and Croda International.

Why Purchase the Report?

  • To visualize the global vaccine adjuvants market segmentation based on product type, route of administration, diseases, end user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global vaccine adjuvants market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global vaccine adjuvants market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Diseases
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of infectious disease to drive global vaccine adjuvant market growth during the forecast period
    • 4.1.2. Restraints
      • 4.1.2.1. High R&D cost for adjuvant development to hamper the market growth
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Particulate Adjuvants
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Adjuvant Emulsions
  • 7.4. Pathogen Components
  • 7.5. Combination Adjuvants
  • 7.6. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Intramuscular*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Oral
  • 8.4. Intradermal
  • 8.5. Subcutaneous
  • 8.6. Intranasal

9. By Diseases

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
    • 9.1.2. Market Attractiveness Index, By Diseases
  • 9.2. Infectious Disease*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Cancer
  • 9.4. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Pharmaceutical and Biotech Companies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Research Institutes
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. InvivoGen*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. OZ Biosciences
  • 13.3. SEPPIC
  • 13.4. SPI Pharma
  • 13.5. Agenus, Inc
  • 13.6. Aphios Corp
  • 13.7. Vaxine Pty Ltd
  • 13.8. Seqirus
  • 13.9. Chemtrade
  • 13.10. Croda International

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us